Intellia Therapeutics Inc. (NASDAQ:NTLA) shares are up on Monday after the company announced a rolling BLA submission to the FDA for its gene-editing therapy, lonvo-z (NTLA-2002), which is aimed at treating hereditary angioedema.
The news comes following positive topline results from the Phase 3 HAELO trial.
Efficacy Data Show Significant Attack Reduction
80 patients were enrolled, with 52 receiving Lonvo-Z and 28 receiving a placebo. The trial met its primary endpoint.
For the six-month efficacy evaluation period (weeks 5 to 28), a one-time infusion of lonvo-z reduced attacks by 87% versus placebo, with a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm.
The trial met all of its key secondary endpoints with statistical significance.
These included a 62% rate of patients who were entirely attack-free and therapy-free in the Lonvo-Z arm for the six-month efficacy evaluation period, compared with 11% of patients in the placebo arm.
Favorable safety and tolerability data were observed for lonvo-z.
All TEAEs reported as of the data cutoff (February 10, 2026) were mild or moderate, and there were no serious adverse events observed in the lonvo-z arm.
Intellia (NTLA) Rolling BLA Filing For Lonvo-z
The gene-editing company announced that it has initiated a rolling Biologics License Application (BLA) submission to the FDA for lonvo-z, a one-time treatment designed to address hereditary angioedema.
The company aims for a potential U.S. launch in the first half of 2027.
NTLA Technical Outlook: Key Support, Resistance And Momentum
Intellia Therapeutics is currently trading within a 52-week range of $6.83 to $28.25, suggesting it is positioned closer to its lower end, which may indicate a bearish sentiment among investors.
The stock is trading 7.3% below its 20-day simple moving average (SMA), suggesting short-term weakness, while it is 18.8% above its 100-day SMA, indicating some intermediate-term strength.
The relative strength index (RSI) currently sits at 47.16, reflecting a neutral momentum, which suggests that the stock is not in overbought or oversold territory. This positioning indicates that traders may be waiting for clearer signals before making significant moves.
- Key Resistance: $15.50 — This level may act as a barrier for upward movement.
- Key Support: $12.50 — A critical level where buying interest may emerge.
Intellia has shown a 12-month performance of 60.73%, reflecting a strong recovery from its lows, but the current price action suggests that traders are cautious as they assess the implications of the recent news.
How Intellia (NTLA) Ranks On Momentum Versus Peers
Below is the Benzinga Edge scorecard for Intellia Therapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 36.58) — Stock is underperforming the broader market.
The Verdict: Intellia Therapeutics’s Benzinga Edge signal reveals a weak momentum profile, indicating challenges in gaining traction in the current market environment.
NTLA Price Action: Intellia Therapeutics shares were up 5.28% at $14.35 at the time of publication on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments